Spectranetics bags Covidien's drug-coated balloon
This article was originally published in Clinica
Executive Summary
As its takeover by Medtronic draws closer, Covidien has agreed to sell its Stellarex drug-coated balloon platform to Spectranetics for the seemingly bargain price of $30m. The move is thought to be an attempt to placate antitrust regulators and is subject to the closure of the $43bn mega-deal, which is expected in early 2015.